Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masataka Okamoto

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 15, 2014
[The progress of laboratory medicine and diagnostic procedures in lymphoma and its future prospects]Masataka Okamoto
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2011
Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma, not otherwise specifiedNozomi Niitsu, Hirokazu Nakamine, Masataka Okamoto
Cancer Science|March 10, 2010
Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexateNozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, et al.
Leukemia Research|May 21, 2008
Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphomaNozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, et al.
Cancer Science|November 29, 2008
Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphomaNozomi Nitsu, Masataka Okamoto, Ikuo Miura, et al.
Hematological Oncology|April 9, 2008
Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomasNozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, et al.
Hematological Oncology|September 8, 2006
Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphomaNozomi Niitsu, Masataka Okamoto, Mika Kohori, et al.
Hematological Oncology|March 18, 2010
Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphomaNozomi Niitsu, Mika Kohri, Yuki Hagiwara, et al.
Biochimica Et Biophysica Acta|August 17, 2010
Inhibitory activities of the heterotrimers formed from two α-type phospholipase A2 inhibitory proteins with different enzyme affinities and importance of the intersubunit electrostatic interaction in trimer formationMasanori Nishida, Masataka Okamoto, Ai Ohno, et al.
Annals of Hematology|March 7, 2006
Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphomaNozomi Niitsu, Masataka Okamoto, Sadao Aoki, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 15, 2014
[The progress of laboratory medicine and diagnostic procedures in lymphoma and its future prospects]Masataka Okamoto
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2011
Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma, not otherwise specifiedNozomi Niitsu, Hirokazu Nakamine, Masataka Okamoto
Cancer Science|March 10, 2010
Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexateNozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, et al.
Leukemia Research|May 21, 2008
Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphomaNozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, et al.
Cancer Science|November 29, 2008
Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphomaNozomi Nitsu, Masataka Okamoto, Ikuo Miura, et al.
Hematological Oncology|April 9, 2008
Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomasNozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, et al.
Hematological Oncology|September 8, 2006
Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphomaNozomi Niitsu, Masataka Okamoto, Mika Kohori, et al.
Hematological Oncology|March 18, 2010
Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphomaNozomi Niitsu, Mika Kohri, Yuki Hagiwara, et al.
Biochimica Et Biophysica Acta|August 17, 2010
Inhibitory activities of the heterotrimers formed from two α-type phospholipase A2 inhibitory proteins with different enzyme affinities and importance of the intersubunit electrostatic interaction in trimer formationMasanori Nishida, Masataka Okamoto, Ai Ohno, et al.
Annals of Hematology|March 7, 2006
Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphomaNozomi Niitsu, Masataka Okamoto, Sadao Aoki, et al.
Pageof 7